2'-溴-2'-脱氧-D-尿苷 | 4753-02-0

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 中文名称: 2'-溴-2'-脱氧-D-尿苷
• 中文别名: 2′-溴-2′-脱氧尿苷
• 英文名称: 2'-bromo-2'-deoxyuridine
• 英文别名: 2'-bromo-2'-deoxy-uridine；1-(2-Brom-2-deoxi-β-D-ribofuranosil)uracil；2¹-Brom-2¹-desoxyuridin；2'-Brom-2'-desoxy-uridin；2'-Bromo-2'-desoxyuridin；2'-Brom-2'-deoxy-uridin；1-[(2R,3R,4R,5R)-3-bromo-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 4753-02-0
• 化学式: C₉H₁₁BrN₂O₅
• 分子量: 307.101
• InChiKey: FEUDNSHXOOLCEY-XVFCMESISA-N

物化性质

• 熔点：
  186-190 °C (decomp)
• 密度：
  1.882±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2'-溴-2'-脱氧-D-尿苷 在 咪唑 、 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.5h， 生成 5'-O-(tert-butyldimethylsilyl)-2'-deoxyuridine
  参考文献：
  名称：

  Nucleic Acid Related Compounds. 91. Biomimetic Reactions Are in Harmony with Loss of 2‘-Substituents as Free Radicals (Not Anions) during Mechanism-Based Inactivation of Ribonucleotide Reductases. Differential Interactions of Azide, Halogen, and Alkylthio Groups with Tributylstannane and Triphenylsilane¹

  摘要：

  The initial step in the mechanism-based inactivation of ribonucleotide reductases by 2'-chloro-2'-deoxynucleotides is abstraction of H3' by a proximal free radical on the enzyme. The C3' radical is postulated to undergo spontaneous loss of chloride, and the resulting cationic radical loses a proton to give a 3'-keto intermediate. Successive beta-eliminations produce a Michael acceptor which causes inactivation. This hypothesis would predict rapid loss of mesylate or tosylate anions from C2', but sluggish loss of azide or thiomethoxide. in contrast, loss of azido and methylthio radicals from C2' should occur readily whereas homolysis to give (methyl or tolylsulfonyl)oxy and fluoro radicals should be energetically prohibitive. Protected 3'-O-(phenoxythiocarbonyl)-2'-substitute nucleosides were treated with tributylstannane/AIBN or triphenylsilane/dibenzoyl peroxide in refluxing toluene. The 2'-O-(mesyl and tosyl) and 2'-fluoro compounds underwent direct radical-mediated hydrogenolysis of the thionocarbonate group to give 3'-deoxy-2'-substituted products, whereas 2'-(azido, bromo, chloro, iodo, and methylthio)-3'-thionocarbonates gave 2',3'-didehydro-2',3'-dideoxy derivatives via loss of 2'-substituents from an incipient C3' radical. These results are in harmony with loss of radicals, but not anions, from C2'. The well-known radical-mediated hydrogenolytic cleavage of halogen and methylthio (slow) groups from C2' of the S'-hydroxy (unprotected) precursors and reduction of 2'-azides to amines occurred with tributylstannane/AIBN. Triphenylsilane/dibenzoyl peroxide gave parallel (but slower) hydrogenolysis with the 2'-(iodo, bromo, and methylthio) compounds, but cleavage of the 2'-chloro group was very slow and no reduction of 2'-azides to amines was detected. Rather, the latter system effected slow hydrogenolytic removal of the 2'-azido group. Thus, chemoselective differentiation of certain functional groups is possible with triphenylsilane and tributylstannane. Reduction of azides to amines with tributylstannane is known, but hydrogenolytic deazidation (slow) with triphenylsilane in the absence of amine formation appears to be novel.

  DOI：

  10.1021/ja962117m
• 作为产物：
  描述：

  1-(3,5-di-O-acetyl-2-bromo-2-deoxy-β-D-ribofuranosyl)-uracil 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以0.51 g的产率得到2'-溴-2'-脱氧-D-尿苷
  参考文献：
  名称：

  Bhat, K. S.; Rao, A. S., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1983, vol. 22, # 7, p. 678 - 679

  摘要：

  DOI：

文献信息

• Anti-HCV nucleoside derivatives
  申请人：——

  公开号：US20030008841A1

  公开（公告）日：2003-01-09

  The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.

  本发明涉及新颖和已知的嘌呤和嘧啶核苷衍生物，已发现这些衍生物对丙型肝炎病毒（HCV）具有活性。本发明声明利用这些衍生物治疗HCV感染，以及本文所披露的新颖核苷衍生物。
• Influence of substituent groups in regioselective acylation of nucleosides by Novozym 435 lipase
  作者：Zhao-Yu Wang、Yan-Hong Bi、Xiang-Qian Li、Min-Hua Zong

  DOI：10.1016/j.procbio.2013.06.022

  日期：2013.8

  comparative study on the substrate recognition was conducted successfully in Novozym 435-mediated acylation of various 2′- or 5-substituted nucleosides with acyl donors carrying different aliphatic chain lengths (C6, C10, and C14). The unexpected results revealed that the physicochemical property of the substituents (such as the size, hydrophobicity, and substitutional position) in nucleosides profoundly influenced

  在 Novozym 435 介导的各种 2' 或 5 取代核苷与携带不同脂肪链长度（C6、C10 和 C14）的酰基供体的酰化中，成功地进行了底物识别的比较研究。出乎意料的结果表明，核苷中取代基的物理化学性质（如大小、疏水性和取代位置）对酶的行为产生了深远的影响。源自核苷 2'-或 5-位取代基的不同底物结合模式可以解释这一点。此外，除了脂肪酶活性位点的几何构型之外，控制区域选择性的另一个可能因素可能归因于取代基和酰基供体之间的相互作用。
• [EN] TRANSLATIONAL ENHANCERS AND RELATED METHODS<br/>[FR] AMPLIFICATEURS DE TRADUCTION ET PROCÉDÉS ASSOCIÉS
  申请人：EFFECTOR THERAPEUTICS INC

  公开号：WO2021001739A1

  公开（公告）日：2021-01-07

  The present disclosure relates to novel translational enhancers comprising an eukaryotic initiation factor 4E (eIF4E) ligand attached to a dinucleotide. The present disclosure also relates to RNA molecules (e.g., mRNAs) comprising the novel translational enhancers, which imparts properties to the RNA molecules that are advantageous to therapeutic development, methods of using RNA molecules comprising such novel translational enhancers for therapeutic uses, as well as kits containing the translational enhancers.

  本公开涉及包含连接到二核苷酸的真核起始因子4E（eIF4E）配体的新型转译增强剂。本公开还涉及包含这些新型转译增强剂的RNA分子（例如mRNA），这些RNA分子赋予了对治疗开发有利的特性，以及使用包含这些新型转译增强剂的RNA分子进行治疗用途的方法，以及包含转译增强剂的试剂盒。
• [EN] POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA<br/>[FR] POLYNUCLÉOTIDES CODANT POUR LA LIPOPROTÉINE LIPASE DESTINÉS AU TRAITEMENT DE L'HYPERLIPIDÉMIE
  申请人：MODERNATX INC

  公开号：WO2017201333A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of hyperlipidemia. mRNAs for use in the invention, when administered in vivo, encode human lipoprotein lipase (LPL), isoforms thereof, functional fragments thereof, and fusion proteins comprising LPL. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto, mRNA therapeaies of the invention increase and/or restore deficient levels of LPL expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of triglycerides associated with deficient LPL activity in subjects.

  该发明涉及mRNA疗法用于治疗高脂血症。该发明中使用的mRNA，在体内给予时，编码人类脂蛋白脂肪酶（LPL）、其异构体、其功能性片段以及包含LPL的融合蛋白。该发明中的mRNA最好被封装在脂质纳米颗粒（LNPs）中，以实现对受试者的细胞和/或组织的高效传递，当给予治疗时，该发明中的mRNA疗法增加和/或恢复受试者中LPL表达和/或活性的不足水平。该发明中的mRNA疗法进一步降低与受试者中LPL活性不足相关的甘油三酯水平。
• [EN] POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME<br/>[FR] POLYNUCLÉOTIDES CODANT POUR JAGGED1 POUR LE TRAITEMENT DU SYNDROME D'ALAGILLE
  申请人：MODERNATX INC

  公开号：WO2017201342A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof, functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

  该发明涉及用于治疗艾拉吉尔综合征（ALGS）的mRNA疗法，该发明中使用的mRNA，在体内给予时，编码JAGGED 1（JAG1）、其同工异构体、其功能性片段以及包含JAG1的融合蛋白，该发明的mRNA最好被封装在脂质纳米颗粒（LNPs）中，以实现对受试者的细胞和/或组织的有效传递，当向受试者施用时。该发明的mRNA疗法增加和/或恢复受试者中JAG1表达和/或活性的不足水平。该发明的mRNA疗法进一步降低与受试者中JAG1活性不足相关的有毒代谢物水平。